In the past week, CRDF stock has gone down by -27.48%, with a monthly gain of 58.37% and a quarterly surge of 44.78%. The volatility ratio for the week is 13.31%, and the volatility levels for the last 30 days are 12.57% for Cardiff Oncology Inc The simple moving average for the past 20 days is 15.98% for CRDF’s stock, with a 22.50% simple moving average for the past 200 days.
Is It Worth Investing in Cardiff Oncology Inc (NASDAQ: CRDF) Right Now?
Moreover, the 36-month beta value for CRDF is 1.84. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CRDF is 61.33M and currently, short sellers hold a 16.22% of that float. On December 26, 2024, CRDF’s average trading volume was 1.91M shares.
CRDF) stock’s latest price update
Cardiff Oncology Inc (NASDAQ: CRDF)’s stock price has decreased by -3.69 compared to its previous closing price of 4.07. However, the company has seen a -27.48% decrease in its stock price over the last five trading sessions. seekingalpha.com reported 2024-12-14 that The ‘Undercovered’ Dozen series highlights lesser-covered stocks, offering fresh investment ideas and sparking community discussions on their potential. Ubiquiti Inc. shows promise with operational improvements, Ready Capital Corporation faces liquidity risks, and TORM plc is crucial despite energy sector volatility. Esperion Therapeutics’ breakout and Cardiff Oncology’s promising trial data present compelling buy opportunities, while Advantest Corporation’s high valuation suggests caution.
Analysts’ Opinion of CRDF
Many brokerage firms have already submitted their reports for CRDF stocks, with Craig Hallum repeating the rating for CRDF by listing it as a “Buy.” The predicted price for CRDF in the upcoming period, according to Craig Hallum is $8 based on the research report published on September 06, 2024 of the current year 2024.
Robert W. Baird gave a rating of “Outperform” to CRDF, setting the target price at $19 in the report published on December 08th of the previous year.
CRDF Trading at 24.97% from the 50-Day Moving Average
After a stumble in the market that brought CRDF to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.94% of loss for the given period.
Volatility was left at 12.57%, however, over the last 30 days, the volatility rate increased by 13.31%, as shares surge +60.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +49.05% upper at present.
During the last 5 trading sessions, CRDF fell by -26.73%, which changed the moving average for the period of 200-days by -2.97% in comparison to the 20-day moving average, which settled at $3.38. In addition, Cardiff Oncology Inc saw 162.16% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRDF starting from Levine James E., who purchase 2,752 shares at the price of $5.42 back on Dec 17 ’24. After this action, Levine James E. now owns 65,316 shares of Cardiff Oncology Inc, valued at $14,905 using the latest closing price.
Levine James E., the Chief Financial Officer of Cardiff Oncology Inc, purchase 2,400 shares at $5.00 during a trade that took place back on Dec 18 ’24, which means that Levine James E. is holding 67,716 shares at $12,000 based on the most recent closing price.
Stock Fundamentals for CRDF
Current profitability levels for the company are sitting at:
- -67.36 for the present operating margin
- 0.55 for the gross margin
The net margin for Cardiff Oncology Inc stands at -62.38. The total capital return value is set at -0.92. Equity return is now at value -67.57, with -56.80 for asset returns.
Currently, EBITDA for the company is -45.01 million with net debt to EBITDA at 0.25. When we switch over and look at the enterprise to sales, we see a ratio of 361.97. The receivables turnover for the company is 1.11for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.74.
Conclusion
To wrap up, the performance of Cardiff Oncology Inc (CRDF) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
